

CSE: AIAI OTCQB: AINMF FRA: 8TV

CORPORATE PRESENTATION September 2023

IMPORTANT - YOU MUST READ THE FOLLOWING BEFORE CONTINUING: The information contained in this presentation has been prepared by NetraMark Holdings Inc. ("NetraMark" or the "Company") and contains confidential information pertaining to the business, operations and assets of the Company. The information contained in this presentation (a) is provided as at the date hereof and is subject to change without notice, (b) does not purport to contain all the information that may be necessary or desirable to fully and accurately evaluate the Company, and (c) is not to be considered as a recommendation by the Company that any person make an investment in the Company. This presentation is not, and under no circumstances is to be construed as, a prospectus, or advertisement or an offering memorandum for securities of the Company. Prospective investors should not assume that this presentation is complete and should refer to the information about the Company set out under its profile on the System for Electronic Document Analysis and Retrieval ("SEDAR") and consult with their own financial, legal, tax and other business advisors before investing in the Company. By accepting and reviewing this presentation, you acknowledge and agree (i) to maintain the confidentiality of this presentation and the information contained herein, (ii) to protect such information in the same manner you protect your own confidential information, which shall be at least a reasonable standard of care and (iii) to not utilize any of the information contained herein except to assist with your evaluation of a potential investment in the Company. The information presented herein was prepared or obtained by the Company. Nothing contained herein is, or should be relied on as, a promise or representation as to the future performance of the Company.

The information presented herein was prepared or obtained by the Company. Nothing contained herein is, or should be relied on as, a promise or representation as to the future performance of the Company.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION AND FORWARD-LOOKING STATEMENTS:

Certain statements in this presentation constitute forward-looking statements and forward looking information within the meaning of applicable Canadian securities legislation (collectively herein referred to as "forward-looking statements"), which can often be identified by words such as "will", "may", "estimate", "expect", "plan", "project", "intend", "anticipate" and other words indicating that the statements are forward-looking. These include statements regarding: the ability of our NetraAl technology to de-risk and increase the efficiency of clinical trials through improved understanding of underlying disease and mechanism of action, to improve patient enrichment studies with smaller population sizes, to better anticipate characteristics of potential placebo responders, to create uniformed data sets from disparate and irregular data, to generate hypotheses from data sets to better inform, plan and optimize clinical trials; expansion of our sales efforts; the number of sales presentations and closed deals; projected recognized revenues and total deal value contracted; expansion of our business development team; achieving cash flow neutral status; the extrapolation of valuation multiples and the support of our board of directors and advisory board.

Such forward-looking statements are expectations only and are subject to known and unknown risks, uncertainties and other important factors that could cause the actual results, performance or achievements of the Company or industry results to differ materially from any future results, performance or achievements implied by such forward-looking statements. Such risks and uncertainties include, among others, the risk factors set out below under "Risk Factors".

These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements which are based on the information available as of the date of this presentation. Forward-looking information contained in this presentation is based on the Company's current estimates, expectations and projections, which the Company believes are reasonable as of the current date. The Company can give no assurance that these estimates, expectations and projections will prove to have been correct. Forward-looking statements contained in this presentation are made as of the date hereof and, except as required by applicable law, the Company assumes no obligation to update or revise them to reflect new events or circumstances.

An investment in the Company is speculative and involves substantial risk and is only suitable for investors that understand the potential consequences and are able to bear the risk of losing their entire investment. Investors should consider the risks of this investment and consult with their own legal, tax and financial advisors with respect to all such risks before making an investment.

CAUTIONARY NOTE REGARDING FUTURE-ORIENTED FINANCIAL INFORMATION: To the extent any forward-looking statement in this presentation constitutes "future-oriented financial information" or "financial outlooks" within the meaning of applicable Canadian securities laws, including statements regarding projected recognized revenues, total deal value contracted and achievement of cash neutral position, as with forward-looking statements generally, they are, without limitation, based on the assumptions and subject to the risks set out above under the heading "Cautionary Note Regarding Forward-Looking Information and Forward- Looking Statements" and under the heading "Risk Factors" below, among others. Such statements are based on several assumptions which may prove to be incorrect, including but not limited to, assumptions about: general business and economic conditions, the demand for our services, the effectiveness of our technology, the number and the frequency of meetings with potential customers in a month, the percentage of small, medium and larger prospects (by revenue), the expected time to close on a deal, the deal conversion rate, the project value and timing of recognition of revenues associated with any customer agreements, our pace of delivery of results, and our ability to attract and retain key personnel which are important to the relationships we will pursue and our cash needs. The foregoing list of assumptions is not exhaustive. Although NetraMark believes that these assumptions were reasonable when made, because these assumptions are subject to significant uncertainties and contingencies which are difficult or impossible to predict and are beyond the Company's control, NetraMark cannot assure that it will achieve the projections described in the forward looking statements. The process for estimating the Company's revenue and cash flow requires the use of judgment in determining the appropriate assumptions and estimates. These estimates and assumptions may be revised as additional information becomes available and as additional analyses are performed. In addition, the assumptions used in planning may not prove to be accurate, and other events and factors may materially affect the Company's financial condition or results of operations. The purpose of the financial outlooks included herein are to provide information about management's current expectations and plans relating to the future. The information may not be appropriate for other purposes.

The Company's actual financial position and results of operations may differ materially from management's current expectations and, as a result, the Company's revenue, deal value and cash flow position may differ materially from what is provided in this presentation. Such information is presented for illustrative purposes only and may not be an indication of the Company's actual financial position or results of operations. The forward looking financial information contained in this presentation has been approved by management as of December 1, 2022.

THIRD PARTY INFORMATION: This presentation includes market and industry data which was obtained from various publicly available sources and other sources believed by the Company to be true. Although the Company believes it to be reliable, the Company has not independently verified any of the data from third-party sources referred to in this presentation, or analyzed or verified the underlying reports relied upon or referred to by such sources, or ascertained the underlying assumptions relied upon by such sources. The Company does not make any representation as to the accuracy of such information.

RISK FACTORS: There are a number of risk factors as set out below that could cause future results of the Company to differ materially from those described herein. The risks and uncertainties described herein are not the only ones the Company to differ materially from those described herein. faces. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company's business. If any of the following risks actually occur, the Company's business may be harmed, and its financial condition and outlooks and results of operations may suffer significantly.

- NetraMark has a history of operating losses, and we expect to continue to incur losses over the next several years.
- NetraMark's limited operating history may make it difficult for you to evaluate the success of its business to date and to assess our future viability, which may depend on us obtaining additional capital, which might not be available on economically acceptable terms, or at all.
- Our interim and annual results may fluctuate significantly, which could adversely impact the value of our common shares.
- NetraMark's sales and financial forecasts may prove to be inaccurate. We may need to raise additional capital, which may cause dilution to our existing shareholders, restrict our operations or cause us to relinquish valuable rights.
- We are substantially dependent on the NetraMark products to deliver our products and services. The NetraMark platform may fail to discover valued enrichment criteria that positively impact the clinical trial process for our clients.
- Defects or disruptions in the NetraMark products and its associated algorithms and machine learning models could result in diminishing efficacy of our sub-population identification work and therefore we may discover a reduction in our revenues.
- If we cannot maintain existing clients and/or attract new clients or enter into new collaborations, our business could be adversely affected.
- We face competition, which may result in others discovering AI based methods that are more successful than ours, requiring us to rapidly adapt our approach and implement significant technological change and respond to introductions of new products and technologies by competitors to remain competitive.
- Pre-clinical and clinical development involves a lengthy and expensive process with uncertain outcomes. Our strategic partners' pre-clinical and clinical programs may experience delays or may never advance, which would adversely affect their ability or interest to engage or utilize the NetraMark technology.
- Our internal information technology systems, or those of our third-party vendors (including providers of cloud-based infrastructure), contractors or consultants, may fail or suffer security breaches, loss or leakage of data and other disruptions, which could result in a material disruption of our services, compromise sensitive information related to our business, or prevent us from accessing critical information, potentially exposing us to liability or otherwise adversely affecting our business.
- The Company's insurance is subject to coverage limits and exclusions and may not be available for the risks and hazards to which the Company is exposed. If the Company were to incur substantial liability and such damages were not covered by insurance or were in excess of policy limits, or if the Company were to incur such liability at a time when it is not able to obtain liability insurance, its business, results of operations and financial condition could be materially adversely affected.
- The effects of health epidemics, including the ongoing COVID-19 pandemic, in regions where we, or the third parties on which we rely, have business operations could adversely impact our business as well as the business or operations of third parties with whom we conduct business.
- Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and share price.
- The regulatory approval processes of the relevant regulatory authorities are lengthy, time consuming and inherently unpredictable. If the third parties with which we work are not able to obtain, or if there are delays in obtaining, required regulatory approvals for their drug candidates, they will not be able to commercialize, or will be delayed in commercializing, drug candidates, and our ability to generate revenue will be materially impaired.
- NetraMark has invested, and we expect to continue to invest, in research and development efforts that further enhance our technology. If the return on these investments is lower or develops more slowly than we expect, our revenue and results of operations may suffer.
- The market opportunities for clients that may use the NetraMark technology may be smaller than we anticipated.
- NetraMark has in the past, and we may in the future, acquire other companies or technologies, which could divert our management's attention, result in additional dilution to our shareholders and otherwise disrupt our operations and adversely affect our operating results.
- Past performance by any member or members of our management team, board of directors and advisory board may not be indicative of future performance.
- Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel including to achieve our business development goals.
- We may be unable to manage our current and future growth effectively, which could make it difficult to execute our business strategy.
- If securities or industry analysts do not publish research or publish inaccurate or unfavourable research about our business, our share price and trading volume could decline.
- Current and future healthcare legislative reform measures may have a material adverse effect on our business and results of operations.
- Current and future artificial intelligence legislative reform measures may have a material adverse effect on our business and results of operations.
- If we are unable to obtain, maintain, enforce and protect our intellectual property, competitors could develop and commercialize technology and products similar or identical to ours, the value of our business, may be adversely affected.
- Some elements of the NetraMark technology relies on third-party software, including open-source software ("OSS"), and any failure to comply with the terms of one or more of our commercial OSS licenses could adversely affect our business, subject us to litigation, or create potential liability.
- Our registered trademarks or unregistered brands or trade names may be challenged, infringed, diluted, tarnished, circumvented or declared generic or determined to be infringing on other marks.
- We or our existing or future collaborators may become involved in lawsuits to protect or enforce our intellectual property rights, which could be expensive, time consuming and unsuccessful. Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.
- We may be subject to claims by third parties asserting that our employees, consultants or contractors have wrongfully used or disclosed confidential information of third parties, or we have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting we have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property.
- Compliance with global privacy and data security requirements could result in additional costs and liabilities to us or inhibit our ability to collect and process data globally, and the failure to comply with such requirements could subject us to significant fines and penalties, which may have a material adverse effect on our business, financial condition or results of operations.
- Our internal controls may not be sufficiently developed to prevent errors (including accounting- and tax-related errors), inefficiencies and compliance violations. If we discover deficiencies in our internal control systems, we may be required to undertake corresponding corrections, incur unexpected costs and trust in our business and operations may be adversely affected. If we fail to comply with applicable laws and regulations, we may breach representations made to our collaborators, and regulatory authorities may require us to take remedial action. In addition, such violations may be punishable by criminal and civil sanctions, including substantial fines, and harm our reputation.
- There may not be a liquid market for our common shares that will persist. Consequently, investors may not be able to sell their common shares at or above the price at which they acquired them. The price of the common shares may be volatile, and investors may lose all or part of their investments.

The NetraMark vision is to have a material impact on the current 12% clinical trial success rate and serve the pharmaceutical industry's demands for the efficient development of novel therapeutics and medicines.

We have assembled a highly experienced leadership team

OFFICERS

George Achilleos



Chief Executive Officer

George is a seasoned Business Executive with 25+ years of experience, that began in the technology sector at IBM. He has led over \$50M of business deals and transactions and has generated over \$70M+ of revenue in his career. He has been in senior executive positions in the Digital Strategy, E-Commerce, Nano Technology and Retail industries and has served in advisor board roles in the media, clean energy and plant-based foods sectors. He holds a Bachelor of Commerce from The University of Calgary.

Dr. Luca Pani



Chief Innovation and Regulatory Officer

Dr. Pani is an academic both at the University of Miami in the United States and in Modena, Italy, and the former director-general of the Italian Medicines Agency (AIFA) (2011 to 2016), where he managed a multibillion-dollar budget for drug expenditures and negotiations on behalf of the Italian national health system. Dr. Pani was the vicepresident for regulatory strategy and market access innovation at VeraSci, where, among other matters, provided scientific strategic planning on the FDA (U.S. Food and Drug Administration) qualification program for the Pathway eClinical platform. This supported the company for a highly successful \$330-million (U.S.) exit to WCG Clinical, a leader in the pharmaceutical services sector.

Josh Spiegel



President

25-plus years of experience in finance, sales and corporate strategy, with a strong background in health care, business services and technology. Prior to joining NetraMark, Mr. Spiegel was the vicepresident of business strategy at VeraSci, where he leveraged his experience to provide strategic planning and oversight of commercial operations, including the launch of the Pathway eClinical platform and positioned the company for a highly successful \$330-million (U.S.) exit to WCG Clinical, a leader in the pharmaceutical services sector.

Dr. DJ Cook



Chief Medical Officer

D.J. Cook MD, PhD is a neurosurgeon and neuroscientist at Queen's University where he is division head and chair of neurosurgery. Dr. Cook completed his MD, PhD and residency at the University of Toronto and undertook fellowship training at Stanford University in Cerebrovascular and Skull Base Surgery. Dr. Cook's present research is focused on the development of predictive imaging, physiological and behavioural biomarkers in stroke and traumatic brain injury. His work includes the use of multi-sequence MRI analysis using artificial intelligence algorithms to derive novel insights into mechanisms of disease and to monitor recovery and therapy.

Dr. Joseph Geraci



Chief Technology Officer / Chief Scientific Officer and Director

Co-Founder of NetraMark, mathematician, medical scientist, and quantum machine learning specialist with postdocs in machine learning, oncology and neuropsychiatry. He is associated with the department of Molecular Medicine and Pathology at Queen's University in Ontario, Canada, and the Centre for Biotechnology and Genomics Medicine Medical College of Georgia, USA.

Swapan Kakumanu



Chief Financial Officer

Mr. Kakumanu brings over 25 years of senior finance and operations experience. He has served at senior executive management levels, both in public and private companies in high-growth technology, blockchain, manufacturing, trading and oil field services industries. He has held senior management roles as president, chief executive officer and chief financial officer, where he has played a key role in raising over \$200-million through various financing vehicles, including debt, convertible debt, equity and other non-dilutive instruments both in the private and public markets.

We have assembled a highly experienced advisory team

STRATEGIC ADVISORS

Dr. Larry Alphs



Advisory Board Member

Seasoned pharmaceutical industry veteran having served in leadership roles at major industry firms. Specifically, as Executive Director at Pfizer, Therapeutic Area Lead at Johnson and Johnson, Director at Novartis and currently Sr VP CNS Development at Denovo Biopharma.



Dr. Rizk is a highly accomplished professional with a career spanning over two decades. She has held key leadership roles in renowned organizations including Chief Strategy Officer at Medable, Sr. VP at IQVIA, Global VP CRO Strategic Alliance Partner Business at Oracle and Global Program Director at Medidata Solutions. Dr.Rizk was awarded with the PharmaVOICE 100 most inspiring leaders as a leading change agent in 2021.

Abhishek Agrawal



Advisory Board Member

Has held leadership roles at GSK and Novartis launching over five new molecular entities (NMEs) and is an active advisor with the Alzheimer's Drug Discovery Foundation (ADDF), Gates Ventures and Zoic Capital. Mr. Agrawal, also brings a deep management consulting base from IQVIA, Strategic Decisions Group (SDG) and Bionest Partners; where he led several large R&D and commercial portfolio optimization projects for Pfizer, Johnson &Johnson, Biogen and Genentech. Dr. MaryAnne Rizk

Advisory Board Member

The AI pharmaceutical space

Key areas of application:

- 1. There is a real challenge identifying molecules that address disease
- 2. Clinical trial de-risking

We believe there is significant opportunity to improve the clinical trial process and reduce the associated cost

From drug discovery through FDA approval, developing a new medicine takes, on average, 10 to 15 years and costs \$2.6 billion USD.* Less than 12% of the candidate medicines that make it into Phase I clinical trials are approved by the FDA.




Sources: Chart Pack Biopharmaceuticals in Perspective Fall 2020

Sources: PhRMA adaptation of DiMasi JA et al¹²; Tufts CSDD¹³; FDA¹⁴ Key: IND=Investigational new drug application, NDA=New drug application, BLA=Biologics license application *The average R&D cost required to bring a new FDA-approved medicine to patients is estimated to be \$2.6 billion over the past decade (in 2013 dollars), including the cost of the many potential medicines that do not make it through to FDA approval.


	CLINICAL TRIALS		FDA REVIEW	POST-APPROVAL RESEARCH & MONITORING
I	PHASE II	PHASE III		PHASE IV
	I NET	FRAMARK	FD APPRO MEDI	OVED
			NDA / BLA SUBMITTED	ł
	NUMBER OF VOLUNTEERS		NDA / BLA SUB	
	HUNDREDS	THOUSANDS		

The clinical trial market is robust, growing and large



The number of cumulative clinical trials over time¹

Global Clinical Trial Support Services (in USD Billions)²




1) Source: https://ClinicalTrials.gov

2) Sources: https://www.researchandmarkets.com/reports/5415476/clinical-trials-support-services-market-

size?gclid=Cj0KCQjwlumhBhClARIsABO6p-w6bbiqRWsJkIPPzEzU2CwZwZeu2x0OUZctGKYifyZrBfb5bkeazQUaAv3gEALw_wcB

Number of interventional clinical studies, past 12 months¹







The core issues

- Phase 2 trials not necessarily predictive of later phase pivotal studies
- Observed or potential adverse events that can derail programs
- Lack of separation in indications known for placebo response
- Unexpected results for diseases with heterogenous populations
- Compound advanced to efficacy trials that do not fully demonstrate the effect size/significance of the innovative treatment
- Study recruitment challenges extending timelines


The challenge of using AI for clinical trials

The challenge centers around the ability to apply Al methods to small datasets and extract statistically significant insights that can be utilized to enrich future studies and reduce the associated costs



Over 95% of trials have less than 1,000 participants

Extracting statistically relevant findings from smaller population data sets to provide actionable insights for clinical trials is challenging.



Cumulative # of trials by anticipated # of participants (1999 – 2021)*

* https://www.who.int/observatories/global-observatory-on-health-research-and-development/monitoring/number-oftrial-registrations-by-year-location-disease-and-phase-of-development CSE: AIAI OTCQB: AINMF FRA: 8TV

10 1 0 0

0

0 0

10 1 0

10 1 0

10 1

10

NODE 02

10 1 0

BLOCK 01



Unless there is a massive effect size in the data or a large sample size, traditional methods have limitations

Traditional methods:

- T-Tests and ANOVA
- Chi-Square Test
- Logistic Regression
- Linear Regression
- Feature selection + Regularization
- Generalized Estimating Equations (GEE)
- Mixed Effects Models
- Random Forest
- Gradient Boosting Machines
- Support Vector Machines
- Neural Networks and Deep Learning
- Various Clustering methods like k-means, t-SNE, **UMAP**
- Principal Component Analysis (PCA)
- **Time Series Analysis**

NetraAl unlocks your existing data

- risks


ullet

 \bullet

NetraAl reveals unique combinations of variables that inform trial design changes to mitigate late phase study


NetraAl uncovers traditionally unobservable relationships between patients in clinical studies by using novel methods in small interventional datasets

NetraAl excels in navigating noisy clinical trial datasets. Instead of overfitting to explain every patient, it identifies and focuses on distinct explainable subgroups within the patient population.



To improve an endpoint effect size, one cannot depend on these blocky patient representations as shown above.

NetraAl will identify patients that require different treatments, react differently to placebo or to drug, and may suffer from unexpected adverse events.



A NetraMark innovation - Attractor Al

At the core of NetraAl exists a new paradigm: Attractor Al

- variables
- ٠
- samples
- ٠ medicine.

• The goal of Attractor AI is to efficiently discover which patients in a clinical trial can be explained according to a question (e.g., drug response) with a special subset of

• It is called Attractor AI because the method essentially pulls patients together that have high dimensional similarities with respect to the question asked

Attractor AI does not forcibly explain everyone but only those that collectively represent a real effect. This is a powerful way to avoid overfitting.

Attractor AI has an ability to learn which special combination of variables are driving different patient profiles even within a very high dimensional and heterogeneous patient data set consisting of thousands of variables but few

Attractor AI produces an output in the form of a hypothesis, e.g., patients who score lower than 5 on the cognition measure and score 1 on both the attention and judgement items (very low) will likely be poor responders to the candidate

The NetraAl difference

NetraAl is a unique machine learning system that provides an intuitive interface for scientists to interact with multimodal datasets to uncover connections related to efficacy, toxicity and placebo response. NetraAl's ability to uncover insights from small datasets is a key differentiator.

In this example, the NetraAl system was used to create hypotheses about which sets of genetic characteristics may best relate and respond to Folfirinox (FFX), a treatment for pancreatic cancer vs Gemcitabine plus nab-paclitaxel (GnP).

showed

*Source of data – OICR ** Folfirinox

*** Gemcitabine + nab-paclitaxel


**** Aung KL, Fischer SE, Denroche RE, Jang GH, Dodd A, Creighton S, Southwood B, Liang SB, Chadwick D, Zhang A, O'Kane GM, Albaba H, Moura S, Grant RC, Miller JK, Mbabaali F, Pasternack D, Lungu IM, Bartlett JMS, Ghai S, Lemire M, Holter S, Connor AA, Moffitt RA, Yeh JJ, Timms L, Krzyzanowski PM, Dhani N, Hedley D, Notta F, Wilson JM, Moore MJ, Gallinger S, Knox JJ. Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial. Clin Cancer Res. 2018 Mar 15;24(6):1344-1354. doi: 10.1158/1078-0432.CCR-17-2994. Epub 2017 Dec 29. PMID: 29288237; PMCID: PMC5968824.

Pancreatic Cancer treatment study


Patient numbers in the dataset*


	Complete Response	Partial Response	Stable Disease	Progressive Disease	Totals
Treatment Groups	1	70	98	49	218
FFX**	0	41	55	33	129
GnP***	1	29	43	16	89

Perspective 1 - NetraMap



Network Map of Driver Genes





The role of NetraAl

REDUCED POPULATION HETEROGENEITY

Biomarker verification to reduce variability and increase study power.

PROGNOSTIC ENRICHMENT

Selecting patients more likely to have measurable clinical endpoints.

PREDICTIVE ENRICHMENT

Identifying patients more likely to respond to the treatment.

NetraAl Decision Support Solutions

Phase I offering

 \bullet

Phase II / III offering ullet

- dossier

• NetraAl evaluates existing Phase I data and client MOA. Recommends assays (methylation, RNA-Seq, fMRI, EEG, microbiome) and outcome measures (clinical scales) to optimize the upcoming pre pivotal (Phase II studies)

• The Assessment develops recommendations and proposes hypotheses to set the stage for successful patient enrichment strategies (maximize return of phase II study investment)

• Consultive report deliverable that maximizes learnings from upcoming pre pivotal study to de-risk expensive later stage of clinical trial

• Create patient stratification datasets to inform enrichment criteria and employ placebo effect mitigation solutions

• Enhance patient screening plan and recruitment strategies

• Biomarker data support for regulatory agency review and payer value

AIAI CSE: OTCQB: AINMF FRA: 8TV

IMNNNNNM NMNI MNNNNNM NMN NMNNMNMI IMNNNNNM NMI NMN NMNNMN IMNNNNNM IMNNNNN VMNNNNNM N INMN NMNNMNM MNNNNNM NMN NMN NMNNMNN IMNNNNNM NM INMN NMNNMNMM INMN NMNNMNMM NMNNNNNM NMNNI INMN NMNNMNMM IMNNNNNM NMNN NMN NMNNMNMM NMNNNNNM NMNN

The Target Engagement

Biotech or pharma company programs with clinical data in an indication of experience in these areas:

- Oncology
- Neurology
- Psychiatry
- Metabolic
- \bullet

The Target Audience

Leverage high level relationships & attend disease specific conferences to engage with:

 \bullet

- **SAB Members**
- \bullet
- **Program Leads**

The Channel Strategy

Create a network effect by building a robust reseller channel with leading Contract Research Organizations (CROs)

Rare & Orphan Disorders


Chief Science Officers

Chief Medical Officers

Heads of Translational Medicine

AIAI CSE: OTCQB: AINMF FRA: 8TV

The NetraMark Workflow



	NetraGPT Report	••
Internation Internation	RK	
Disease Name:	Amyotrophic Lateral Sclerosis Bulbar Subtype	Disease report
NetraAl Hypothesized Genes:	TMEM14A, TBC1D20, RAB1, RAB2, TDP-43	
Non-gene Variables:		Non-Gene report
Amyotrophic Lateral Sclerosis subtype of ALS specifically af ALS, including TMEM14A, TBO TMEM14A is a gene that encor TMEM14A that was associate TBC1D20 is a gene that encor associated with an increased RAB1 and RAB2 are genes th that were associated with an development of ALS. TDP-43 is a gene that encode (2008) found that TDP-43 wa In conclusion, several genes h research is needed to fully un References: van Blitterswijk, M., van Es, M Human molecular genetics, 2 Brenner, D., Müller, K., Wielar 5), e28. https://doi.org/10.10 Kabashi, E., Valdmanis, P. N., I	associated with Amyotrophic Lateral Sclerosis Bulbar Subtype: s (ALS) is a neurodegenerative disease that affects the motor neurons in the brain and fects the muscles involved in speech, swallowing, and breathing. Several genes have b C1D20, RAB1, RAB2, and TDP-43. odes a transmembrane protein involved in the regulation of calcium signaling. A study d with an increased risk of ALS. However, further research is needed to fully understand des a protein involved in the regulation of intracellular trafficking. A study by Brenner risk of ALS. However, like TMEM14A, further research is needed to fully understand th at encode proteins involved in the regulation of intracellular trafficking. A study by Brinner increased risk of ALS. However, like TMEM14A and TBC1D20, further research is need s a protein involved in RNA processing and regulation. Mutations in TDP-43 have been s mislocalized and aggregated in the motor neurons of ALS patients, suggesting that con- have been identified as potential contributors to the development of ALS, including TM inderstand the role of these genes in the pathogenesis of ALS. I. A., Hennekam, E. A., Dooijes, D., van Rheenen, W., Medic, J., Veldink, J. H. (2012). E 1(17), 3776–3784. https://doi.org/10.1093/hmg/dds199 nd, T., Weydt, P., Böhm, S., Lulé, D., Ludolph, A. C. (2016). NEK1 mutations in familial 93/brain/aww050 Dion, P., Spiegelman, D., McConkey, B. J., Vande Velde, C., Rouleau, G. A. (2008). TAR Nature genetics, 40(5), 572–574. https://doi.org/10.1038/ng.132]	een identified as potential contributors to the development of by van Blitterswijk et al. (2012) identified a rare variant in nd the role of TMEM14A in the development of ALS. et al. (2016) identified a rare variant in TBC1D20 that was he role of TBC1D20 in the development of ALS. enner et al. (2016) identified rare variants in both RAB1 and RAB2 ed to fully understand the role of RAB1 and RAB2 in the didentified as a cause of familial ALS. A study by Kabashi et al. dysfunction of TDP-43 may contribute to the development of ALS. MEM14A, TBC1D20, RAB1, RAB2, and TDP-43. However, further vidence for an oligogenic basis of amyotrophic lateral sclerosis. amyotrophic lateral sclerosis. Brain : a journal of neurology, 139(Pt
Diseases Chat		

Introducing NetraGPT

Output reports that begin to assemble in seconds and conclude within minutes

Improved explainability of the influential variables underlying discovered subpopulations

Additional insights delineating interconnections among variables, the response, and the disease state

References sourced from relevant and contemporary literature

Current Year

Building the sales pipeline

Leverage leadership pharmaceutical network Pharma Targeting outreach Aggressive conference schedule Build CRO channel strategy Sales pipeline lead list build to \$5M+

The information set out above is based on a number of assumptions including that the Company will hold an average of twenty four (24) prospect meetings per quarter, an expected average time to close of six (6) months, the average conversion rate of twenty percent (20%), average revenue per contract between \$75,000 CDN and \$400,000 CDN (depending on scope of work) and to be paid, on average, within thirty (30) to ninety (90) days of milestone completion - See "Cautionary Note Regarding Forward-Looking Information and Forward-Looking Statements", "Cautionary Note Regarding Future-Oriented Financial Information" and "Risk Factors" above. "Contracted Value" equals revenue payable under contracts for services with customers that we have executed other than revenue recognized under IFRS during the applicable period. Contracted Value is subject to our clients' completion of necessary milestones under their research and clinical trial programs so it may not be recognized for many months or at all. The Company does not expect the Projected Contracted Values set out above to be converted to recognized revenue within the fiscal year. There can be no assurance that Contracted Value will be recognized meaning under IFRS and might not be comparable to similar financial measures disclosed by other issuers. The most directly comparable financial measure to Contracted Value in the financial statements of the Company is revenue. Contracted Value is intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS. Management believes that Contracted Value is useful as a supplement to comparable IFRS financial information. Management reviews this metric on a regular basis and uses it, together with financial measures included in the Company's financial statements, to evaluate and manage the performance of the Company and to a count for the value of a contract entered into, but not completed.



50+ Leads in the sales pipeline

Result

10+ CRO channel partner discussions



The Pharmaceutical AI sector is producing high valuation multiples

Comparison	Estimated Revenue	Pre-Money Valuation	Valuation / Rev Multiple
Owkin ¹	2020 ~ \$12.15M	Nov 2021 ~ \$1.12B	~ 92X
ConcertAl ¹	2022 ~ \$53M	Mar 2022 ~ \$1.75B	~ 33X
GNS Healthcare ²	~ \$14M	Jan 2020 ~ \$120M	~ 8.6X
PathAl ³	~ \$93M	May 2021 ~ \$850M	~ 9.1X
Insitro ⁴	~ \$45M	April 2021 ~ \$2.1B	~ 47X
UnlearnAl⁵	~ \$6.7M	Aug 2022 ~150M	~ 22X
Exscientia ⁶	~ \$24.5M	Public Mkt Cap - \$707M	~ 28X
		Average Multiple	~ 34X

1, 2, 3, 4, 5 – Pitchbook

2 <u>https://growjo.com/company/GNS_Healthcare</u>

3 https://growjo.com/company/PathAl

4 https://growjo.com/company/insitro

5 https://growjo.com/company/Unlearn.Al

6 Publicly traded company

See "The Milestones" on page 21 for more information regarding Projected Contracted Value. There can be no assurance that other parties would value the Company on the same basis or apply the same multiples as the comparable companies set out above.



Thank you

For more information, please contact george@netramark.com

STATUTORY RIGHTS OF ACTION

In certain circumstances, purchasers resident in certain provinces of Canada, are provided with a remedy for rescission or damages, or both, in addition to any other right they may have at law, where an offering memorandum (such as this presentation) and any amendment to it contains a misrepresentation. Where used herein, "misrepresentation" means an untrue statement of a material fact or an omission to state a material fact that is required to be stated or that is necessary to make any statement not misleading in light of the circumstances in which it was made. These remedies, or notice with respect to these remedies, must be exercised or delivered, as the case may be, by the purchaser within the time limits prescribed by applicable securities legislation. The following summary is subject to the express provisions of the applicable securities laws, regulations and rules, and reference is made thereto for the complete text of such provisions. Such provisions may contain limitations and statutory defences not described here on which the Company and other applicable parties may rely. Purchasers should refer to the applicable provisions of the securities legislation of their province for the particulars of these rights or consult with a legal advisor.

ONTARIO, NEW BRUNSWICK, NOVA SCOTIA AND SASKATCHEWAN

The following is a summary of rights of rescission or damages, or both, available to purchasers resident in the province of Ontario, New Brunswick, Nova Scotia and Saskatchewan. If there is a misrepresentation herein and you are a purchaser under securities legislation in Ontario. New Brunswick. Nova Scotia and Saskatchewan you have, without regard to whether you relied upon the misrepresentation, a statutory right of action for damages against: (a) the Company; (b) every director of the Company at the date of this offering memorandum or any amendment (with respect to purchasers resident in Saskatchewan, New Brunswick and Nova Scotia); (c) every promoter of the Company at the time this offering memorandum or any amendment thereto was sent or delivered (with respect to purchasers resident in Saskatchewan); (d) every person or company whose consent has been filed respecting the offering, but only with respect to reports, opinions or statements that have been made by them (with respect to purchasers resident in Saskatchewan); (e) every person who or company that signed this offering memorandum or any amendment thereto (with respect to purchasers resident in Saskatchewan, New Brunswick and Nova Scotia); and (f) every person who or company that sells units of the Company on behalf of the Company under this offering memorandum or amendment thereto (with respect to purchasers resident in Saskatchewan), or while still the owner of the securities, for rescission against the Company. This statutory right of action is subject to the following: (a) if you elect to exercise the right of action for rescission, you will have no right of action for damages against the Company; (b) except with respect to purchasers resident in Nova Scotia, no action shall be commenced to enforce a right of action for rescission after 180 days from the date of the transaction that gave rise to the cause of action; (c) no action shall be commenced to enforce a right of action for damages after the earlier of (i) 180 days (with respect to purchasers resident in Ontario) or one year (with respect to purchasers resident in Saskatchewan and New Brunswick) after you first had knowledge of the facts giving rise to the cause of action, and (ii) three years (with respect to purchasers resident in Ontario) or six years (with respect to purchasers resident in Saskatchewan and New Brunswick) after the date of the transaction that gave rise to the cause of action: (d) with respect to purchasers resident in Nova Scotia, no action shall be commenced to enforce a right of action for rescission or damages after 120 days from the date on which payment for the securities was made by you; (e) the Company will not be liable if it proves that you purchased the securities with knowledge of the misrepresentation; (f) in the case of an action for damages, the Company will not be liable for all or any portion of the damages that it proves do not represent the depreciation in value of the securities as a result of the misrepresentations;

BRITISH COLUMBIA, ALBERTA AND QUÉBEC

TERRITORIES

Ontario purchasers.

The statutory right of action described above is in addition to and without derogation from any other right or remedy at law.

RESALE RESTRICTIONS

and (g) in no case will the amount recoverable in such action exceed the price at which the securities were sold to you. The foregoing is a summary only and is subject to the express provisions of the Securities Act (Ontario), the Securities Act (New Brunswick), the Securities Act (Nova Scotia) and the Securities Act (Saskatchewan), and the rules, regulations and other instruments thereunder, and reference is made to the complete text of such provisions contained therein. Such provisions may contain limitations and statutory defenses on which the Company may rely.

Notwithstanding that the Securities Act (British Columbia), the Securities Act (Alberta), and the Securities Act (Québec) do not provide, or require the Company to provide, to purchasers resident in these jurisdictions any rights of action in circumstances where this presentation or an amendment hereto contains a misrepresentation, the Company hereby grants to such purchasers contractual rights of action that are equivalent to the statutory rights of action set forth above with respect to purchasers resident in Ontario.


MANITOBA, NEWFOUNDLAND AND LABRADOR, PELYUKON TERRITORY, NUNAVUT AND THE NORTHWEST

In Manitoba, the Securities Act (Manitoba), in Newfoundland and Labrador the Securities Act (Newfoundland and Labrador), in Prince Edward Island the Securities Act (PEI), in Yukon, the Securities Act (Yukon), in Nunavut, the Securities Act (Nunavut) and in the Northwest Territories, the Securities Act (Northwest Territories) provide a statutory right of action for damages or rescission to purchasers resident in Manitoba, Newfoundland, PEI, Yukon, Nunavut and Northwest Territories respectively, in circumstances where this presentation or an amendment hereto contains a misrepresentation, which rights are similar, but not identical, to the rights available to

The securities described herein are being offered on a private placement basis in reliance upon prospectus and registration exemptions under applicable securities legislation. Resale of the securities offered hereby will be subject to restrictions under the applicable securities legislation, which will vary depending on the relevant jurisdiction. Generally, such

securities may be resold only pursuant to an exemption from the prospectus and registration requirements of applicable securities legislation or pursuant to an exemption order granted by appropriate securities regulatory authorities.

HE NETRAMARK APPROACH



NetraPlay Access and Support

- Study specific subscription engagement
- Populated with data from previous clinical studies and Netra Health Atlas
- Ability for biotech/pharma discovery teams to further confirm MOA
- Visualize effects
- Lifecycle management Discover other potential uses for company IP (Drug repurposing/expansion)
- Visualize and determine causal factors driving treatment

The Value

....



Improved Patient Enrichment

Our disease and symptom specific models allow us to see how patients relate to one another allowing us to include improved confidence levels with smaller population sizes. This helps to prevent poor outcomes and unnecessary utilization for pharma companies. Our NetraPlacebo technology allows clients to better anticipate characteristics of potential placebo responders.

Our technology has the ability to ingest disparate and irregular data and create uniformed datasets that allow clients to derive new insights regarding how patients relate to one another and help empower their data science teams.







De-risk and Increase the Efficiency of Clinical Trials

Our machine learning methodologies are intended to accelerate traditional drug development through improved understanding of the underlying disease and mechanism of action with the expectation for improved clinical trial designs showcasing efficacy and reducing expensive failures.

Maximize Existing Datasets

Hypothesis Generation

Our technology has the ability to generate hypotheses from our own and client data sets to better inform, plan and optimize future phases of clinical trials. This allows clients to ask better questions!

> AIAI CSE: OTCQB: AINMF FRA: 8TV

Placebo Non-Responders

Introducing NetraPlacebo

ullet

ullet

- together
- ullet
- ullet

The top right-hand corner consists of an almost pure group of placebo non-responders to a bipolar depression drug

The bottom left is a mixed group that was repelled away from the pure responder group and attracted

The variables driving this model were based on their attitude towards medication and their desire to get better and 7 other variables from the applied survey

This was utilized to make predictions that were correct ~ 88% of the time about placebo response

> AIAI CSE: OTCQB: AINMF FRA: 8TV